Literature DB >> 23566065

Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome.

Marlies Wallner1, Rodrig Marculescu, Daniel Doberer, Michael Wolzt, Oswald Wagner, Libor Vitek, Andrew C Bulmer, Karl-Heinz Wagner.   

Abstract

Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566065     DOI: 10.1042/CS20120661

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  34 in total

Review 1.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

Review 2.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

3.  Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.

Authors:  Terry D Hinds; Peter A Hosick; Shujuan Chen; Robert H Tukey; Michael W Hankins; Andrea Nestor-Kalinoski; David E Stec
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-01-17       Impact factor: 4.310

Review 4.  Biliverdin reductase and bilirubin in hepatic disease.

Authors:  Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-01       Impact factor: 4.052

5.  RNA sequencing in human HepG2 hepatocytes reveals PPAR-α mediates transcriptome responsiveness of bilirubin.

Authors:  Darren M Gordon; Thomas M Blomquist; Scott A Miruzzi; Robert McCullumsmith; David E Stec; Terry D Hinds
Journal:  Physiol Genomics       Date:  2019-05-10       Impact factor: 3.107

Review 6.  Bilirubin Safeguards Cardiorenal and Metabolic Diseases: a Protective Role in Health.

Authors:  Terry D Hinds; David E Stec
Journal:  Curr Hypertens Rep       Date:  2019-10-10       Impact factor: 5.369

Review 7.  Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications.

Authors:  John A McClung; Lior Levy; Victor Garcia; David E Stec; Stephen J Peterson; Nader G Abraham
Journal:  Pharmacol Ther       Date:  2021-09-06       Impact factor: 12.310

Review 8.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

Review 9.  Heme oxygenase-1: a metabolic nike.

Authors:  Barbara Wegiel; Zsuzsanna Nemeth; Matheus Correa-Costa; Andrew C Bulmer; Leo E Otterbein
Journal:  Antioxid Redox Signal       Date:  2014-02-27       Impact factor: 8.401

Review 10.  Bilirubin as a metabolic hormone: the physiological relevance of low levels.

Authors:  Justin F Creeden; Darren M Gordon; David E Stec; Terry D Hinds
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-07       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.